Inhaled amikacin

DRUG3 trials

Sponsors

University Hospital, Tours, Asian Institute of Gastroenterology, India, Faculty of Medicine Alexandria University

Conditions

CirrhosisHepatic EncephalopathyPneumonia, Ventilator-AssociatedRespiratory Kidney DiseaseVentilator Associated Pneumonia (VAP)

Phase 3

Study Comparing Inhaled Amikacin Versus Placebo to Prevent Ventilator Associated Pneumonia

CompletedNCT03149640

University Hospital, ToursPneumonia, Ventilator-Associated

Start: 2017-07-19End: 2021-06-17Updated: 2025-12-22

Phase 4

A Study to Evaluate Role of Inhaled Amikacin to Prevent Ventilator Associated Pneumonia in Patients With Cirrhosis

RecruitingNCT06808074

Asian Institute of Gastroenterology, IndiaCirrhosis, Hepatic Encephalopathy, Ventilator Associated Pneumonia (VAP)

Start: 2025-02-12End: 2026-05-31Target: 162Updated: 2025-04-04

Unknown Phase

Inhaled Amikacin for Ventilator Associated Pneumonia (VAP)

RecruitingPACTR201909502649249

Faculty of Medicine Alexandria UniversityRespiratory Kidney Disease

Start: 2019-09-30Target: 45Updated: 2026-09-14

Related Papers

Inhaled Amikacin to Prevent Ventilator-Associated Pneumonia

New England Journal of Medicine2023-10-25100 citations

Inhaled amikacin versus placebo to prevent ventilator-associated pneumonia: the AMIKINHAL double-blind multicentre randomised controlled trial protocol

BMJ Open2021-09-016 citations